{
    "organizations": [],
    "uuid": "803f8cba099f5a2dcbbe7311874c896ad0e14e34",
    "author": "",
    "url": "https://www.reuters.com/article/brief-gemphire-completes-patient-enrollm/brief-gemphire-completes-patient-enrollment-in-indigo-1-trial-idUSFWN1PC0XZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Gemphire Completes Patient Enrollment In Indigo-1 Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 07 PM / in 12 minutes BRIEF-Gemphire Completes Patient Enrollment In Indigo-1 Trial Reuters Staff \nJan 17 (Reuters) - Gemphire Therapeutics Inc: \n* GEMPHIRE COMPLETES PATIENT ENROLLMENT IN INDIGO-1 TRIAL IN SEVERE HYPERTRIGLYCERIDEMIA (SHTG) PATIENTS \n* GEMPHIRE THERAPEUTICS INC - ON TRACK TO REPORT TOP-LINE DATA FROM PHASE 2B TRIAL IN Q2 OF 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-01-17T14:05:00.000+02:00",
    "crawled": "2018-01-17T14:24:32.049+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "completes",
        "patient",
        "enrollment",
        "trial",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "gemphire",
        "therapeutic",
        "inc",
        "gemphire",
        "completes",
        "patient",
        "enrollment",
        "trial",
        "severe",
        "hypertriglyceridemia",
        "shtg",
        "patient",
        "gemphire",
        "therapeutic",
        "inc",
        "track",
        "report",
        "data",
        "phase",
        "2b",
        "trial",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}